The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matthews, D. J.
Right arrow Articles by McKenzie, A. N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matthews, D. J.
Right arrow Articles by McKenzie, A. N. J.
The Journal of Immunology, 2000, 164: 1458-1462.
Copyright © 2000 by The American Association of Immunologists

IL-13 Is a Susceptibility Factor for Leishmania major Infection

David J. Matthews1,*, Claire L. Emson1,*, Grahame J. McKenzie*, Helen E. Jolin*, Jenefer M. Blackwell{dagger} and Andrew N. J. McKenzie2,*

* Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom; and {dagger} Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Cambridge, United Kingdom

Leishmania major infection is useful as an experimental model to define factors responsible for the development and maintenance of Th cell immune responses. Studies using inbred mouse strains have identified that the Th1 response characteristic of C57BL/6 mice results in healing, whereas BALB/c mice fail to control the infection due to the generation of an inappropriate Th2 response. We now demonstrate that IL-13 is a key factor in determining susceptibility to L. major infection. Overexpression of IL-13 in transgenic mice makes the normally resistant C57BL/6 mouse strain susceptible to L. major infection even in the absence of IL-4 expression. This susceptibility correlates with a suppression of IL-12 and IFN-{gamma} expression. Furthermore, using BALB/c mice deficient in the expression of IL-4, IL-13, or both IL-13 and IL-4, we demonstrate that IL-13-deficient mice are resistant to infection and that there is an additive effect of deleting both IL-4 and IL-13.




This article has been cited by other articles:


Home page
Infect. Immun.Home page
A. Maurer-Cecchini, S. Decuypere, F. Chappuis, C. Alexandrenne, S. De Doncker, M. Boelaert, J.-C. Dujardin, L. Loutan, J.-M. Dayer, G. Tulliano, et al.
Immunological Determinants of Clinical Outcome in Peruvian Patients with Tegumentary Leishmaniasis Treated with Pentavalent Antimonials
Infect. Immun., May 1, 2009; 77(5): 2022 - 2029.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. H. Wheat, K. E. Pauken, R. V. Morris, and R. G. Titus
Lutzomyia longipalpis Salivary Peptide Maxadilan Alters Murine Dendritic Cell Expression of CD80/86, CCR7, and Cytokine Secretion and Reprograms Dendritic Cell-Mediated Cytokine Release from Cultures Containing Allogeneic T Cells
J. Immunol., June 15, 2008; 180(12): 8286 - 8298.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Salhi, V. Rodrigues Jr., F. Santoro, H. Dessein, A. Romano, L. R. Castellano, M. Sertorio, S. Rafati, C. Chevillard, A. Prata, et al.
Immunological and Genetic Evidence for a Crucial Role of IL-10 in Cutaneous Lesions in Humans Infected with Leishmania braziliensis
J. Immunol., May 1, 2008; 180(9): 6139 - 6148.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Zhao, B. Zheng, Y. Huang, D. Yang, S. Katzman, C. Chang, D. Fowell, and W.-p. Zeng
Interaction between GATA-3 and the Transcriptional Coregulator Pias1 Is Important for the Regulation of Th2 Immune Responses
J. Immunol., December 15, 2007; 179(12): 8297 - 8304.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
U. Muller, W. Stenzel, G. Kohler, C. Werner, T. Polte, G. Hansen, N. Schutze, R. K. Straubinger, M. Blessing, A. N. J. McKenzie, et al.
IL-13 Induces Disease-Promoting Type 2 Cytokines, Alternatively Activated Macrophages and Allergic Inflammation during Pulmonary Infection of Mice with Cryptococcus neoformans
J. Immunol., October 15, 2007; 179(8): 5367 - 5377.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Silvestre, A. Cordeiro-Da-Silva, N. Santarem, B. Vergnes, D. Sereno, and A. Ouaissi
SIR2-Deficient Leishmania infantum Induces a Defined IFN-{gamma}/IL-10 Pattern That Correlates with Protection
J. Immunol., September 1, 2007; 179(5): 3161 - 3170.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Nagase, K. M. Jones, C. F. Anderson, and N. Noben-Trauth
Despite Increased CD4+Foxp3+ Cells within the Infection Site, BALB/c IL-4 Receptor-Deficient Mice Reveal CD4+Foxp3-Negative T Cells as a Source of IL-10 in Leishmania major Susceptibility
J. Immunol., August 15, 2007; 179(4): 2435 - 2444.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
M. T. M. Roberts
Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment
Br. Med. Bull., July 17, 2006; 75-76(1): 115 - 130.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
H. W. Murray, C. W. Tsai, J. Liu, and X. Ma
Visceral Leishmania donovani Infection in Interleukin-13-/- Mice
Infect. Immun., April 1, 2006; 74(4): 2487 - 2490.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Holscher, B. Arendse, A. Schwegmann, E. Myburgh, and F. Brombacher
Impairment of Alternative Macrophage Activation Delays Cutaneous Leishmaniasis in Nonhealing BALB/c Mice
J. Immunol., January 15, 2006; 176(2): 1115 - 1121.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
M. T. M. Roberts, C. B. Stober, A. N McKenzie, and J. M. Blackwell
Interleukin-4 (IL-4) and IL-10 Collude in Vaccine Failure for Novel Exacerbatory Antigens in Murine Leishmania major Infection
Infect. Immun., November 1, 2005; 73(11): 7620 - 7628.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
H. W. Murray, K. C. Flanders, D. D. Donaldson, J. P. Sypek, P. J. Gotwals, J. Liu, and X. Ma
Antagonizing Deactivating Cytokines To Enhance Host Defense and Chemotherapy in Experimental Visceral Leishmaniasis
Infect. Immun., July 1, 2005; 73(7): 3903 - 3911.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
W. K. Tonui, J. S. Mejia, L. Hochberg, M. L. Mbow, J. R. Ryan, A. S. T. Chan, S. K. Martin, and R. G. Titus
Immunization with Leishmania major Exogenous Antigens Protects Susceptible BALB/c Mice against Challenge Infection with L. major
Infect. Immun., October 1, 2004; 72(10): 5654 - 5661.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. R. Kitching, A. L. Turner, G. R.A. Wilson, K. L. Edgtton, P. G. Tipping, and S. R. Holdsworth
Endogenous IL-13 Limits Humoral Responses and Injury in Experimental Glomerulonephritis but Does Not Regulate Th1 Cell-Mediated Crescentic Glomerulonephritis
J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2373 - 2382.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
B. E. C. Babay, H. Louzir, C. Kebaier, S. Boubaker, K. Dellagi, and P.-A. Cazenave
Inbred Strains Derived from Feral Mice Reveal New Pathogenic Mechanisms of Experimental Leishmaniasis Due to Leishmania major
Infect. Immun., August 1, 2004; 72(8): 4603 - 4611.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
M. Saeftel, A. Krueger, S. Arriens, V. Heussler, P. Racz, B. Fleischer, F. Brombacher, and A. Hoerauf
Mice Deficient in Interleukin-4 (IL-4) or IL-4 Receptor {alpha} Have Higher Resistance to Sporozoite Infection with Plasmodium berghei (ANKA) than Do Naive Wild-Type Mice
Infect. Immun., January 1, 2004; 72(1): 322 - 331.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Noben-Trauth, R. Lira, H. Nagase, W. E. Paul, and D. L. Sacks
The Relative Contribution of IL-4 Receptor Signaling and IL-10 to Susceptibility to Leishmania major
J. Immunol., May 15, 2003; 170(10): 5152 - 5158.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
A. N.J. McKenzie and P. G. Fallon
Decoy Receptors in the Regulation of T Helper Cell Type 2 Responses
J. Exp. Med., March 17, 2003; 197(6): 675 - 679.
[Full Text] [PDF]


Home page
Infect. Immun.Home page
U. M. Padigel and J. P. Farrell
CD40-CD40 Ligand Costimulation Is Not Required for Initiation and Maintenance of a Th1-Type Response to Leishmania major Infection
Infect. Immun., March 1, 2003; 71(3): 1389 - 1395.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
M. L. B. Sousa-Atta, G. S. Salame, A. D'Oliveira Jr, R. P. Almeida, A. M. Atta, and E. M. Carvalho
Immunoglobulin E Antileishmanial Antibody Response in Cutaneous Leishmaniasis
Clin. Vaccine Immunol., January 1, 2002; 9(1): 101 - 104.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
R. G. Titus, G. K. DeKrey, R. V. Morris, and M. B. P. Soares
Interleukin-6 Deficiency Influences Cytokine Expression in Susceptible BALB Mice Infected with Leishmania major but Does Not Alter the Outcome of Disease
Infect. Immun., August 1, 2001; 69(8): 5189 - 5192.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
I. B. Kremer, M. P. Gould, K. D. Cooper, and F. P. Heinzel
Pretreatment with Recombinant Flt3 Ligand Partially Protects against Progressive Cutaneous Leishmaniasis in Susceptible BALB/c Mice
Infect. Immun., February 1, 2001; 69(2): 673 - 680.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. P. Mountford, K. G. Hogg, P. S. Coulson, and F. Brombacher
Signaling via Interleukin-4 Receptor {alpha} Chain Is Required for Successful Vaccination against Schistosomiasis in BALB/c Mice
Infect. Immun., January 1, 2001; 69(1): 228 - 236.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Oshima and R. K. Puri
Characterization of a Powerful High Affinity Antagonist That Inhibits Biological Activities of Human Interleukin-13
J. Biol. Chem., April 27, 2001; 276(18): 15185 - 15191.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.